Genentech:Phase III Data Shows Single-Dose Xofluza Effectively Reduces Influenza Transmission By 32%
25/4 07:23
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that the New England Journal of Medicine has published a detailed analysis of the Phase III CENTERSTONE trial of Xofluza (baloxavir marboxil). The trial met its primary endpoint, showing that a single, oral do...